{"ticker": {"uuid": "d29eea85-226e-41f2-9e71-293657a0fea8", "symbol": "BIAF", "name": "bioAffinity Technologies, Inc.", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Diagnostics & Research"}, "articles": [{"title": "Transcript : BioAffinity Technologies, Inc. - Special Call", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOTkM5dXZ2aEZsejJkNFZfZ05pUU5MMTNRa2FDeFJpVW1JT3ExcEZhclZ3WVJvQmYySUttTmNHUkM1S1g1cm1uRmtLamZmb2d4V2VyVk1PbEN3YVl5QWt5UWU3bko0Vmgza3lpZlFlU0ZlSi0ya3JTalEyREhCc0x1ZVpjeVN3eDhJbkpjdmZxOVMtLS05MC1iZzlWMnJnWmtEMjZiU2NuQ2E?oc=5", "source_name": "marketscreener.com", "published_at": "2026-07-22T01:20:35+00:00", "published_display": "22 Jul 2026 01:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certain Common Stock of bioAffinity Technologies, Inc. are subject to a Lock-Up Agreement Ending on 19-JUL-2026.", "summary": "Certain Common Stock of bioAffinity Technologies, Inc. are subject to a lock-up agreement that concludes on July 19, 2026. This agreement restricts officers and directors from selling or otherwise disposing of their common stock for 31 days, from June 18, 2026, to July 19, 2026, ", "url": "https://www.marketscreener.com/news/certain-common-stock-of-bioaffinity-technologies-inc-are-subject-to-a-lock-up-agreement-ending-on-ce7f51dadf81f427", "source_name": "www.marketscreener.com", "published_at": "2026-07-19T03:41:33", "published_display": "19 Jul 2026 03:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "bioAffinity Technologies Initiates New Study for Expanding CyPath Lung Tech", "summary": "bioAffinity Technologies is launching a pilot study with Brooke Army Medical Center to develop diagnostic tests for asthma and COPD. This research aims to identify inflammatory biomarkers using their proprietary flow cytometry+AI technology to personalize treatment approaches. Th", "url": "https://www.mpo-mag.com/breaking-news/bioaffinity-technologies-initiates-new-study-for-expanding-cypath-lung-tech/", "source_name": "Medical Product Outsourcing", "published_at": "2026-07-15T14:12:13", "published_display": "15 Jul 2026 14:12", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "bioAffinity Technologies Inc Warrant 2022- on bioAffinity Financial Disclosures & SEC Filings", "summary": "This page provides access to SEC filings and other financial documents for bioAffinity Technologies, Inc. (BIAFW). It lists various reports including 10-K, 10-Q, and 8-K filings from 2022 to the projected Q1 FY2026, detailing earnings releases, corporate events, and operational u", "url": "https://www.tradingview.com/symbols/NASDAQ-BIAFW/documents/?exchange=NASDAQ", "source_name": "TradingView", "published_at": "2026-07-11T13:09:56", "published_display": "11 Jul 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BIAF Stock Plunges 77% in 3 Months: Should You Still Hold or Sell?", "summary": "Shares of bioAffinity Technologies, Inc. (BIAF) have plummeted 77% in the past three months, significantly underperforming its industry and market benchmarks despite strong year-over-year growth in commercial sales for its CyPath Lung product and promising preclinical findings. T", "url": "https://uk.finance.yahoo.com/news/biaf-stock-plunges-77-3-173400281.html", "source_name": "Market source", "published_at": "2026-07-09T17:44:04", "published_display": "09 Jul 2026 17:44", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "bioAffinity Technologies\u2019 Quarterly CyPath\u00ae Lung Sales Double to New Record as Commercial Momentum Continues", "summary": "bioAffinity Technologies announced a significant increase in commercial sales for its CyPath\u00ae Lung diagnostic test, with sales for Q2 2026 doubling year-over-year and growing over 30% from the previous quarter. This growth is attributed to increased utilization by existing client", "url": "https://www.businesswire.com/news/home/20260707410622/en/bioAffinity-Technologies-Quarterly-CyPath-Lung-Sales-Double-to-New-Record-as-Commercial-Momentum-Continues", "source_name": "Business Wire", "published_at": "2026-07-08T00:11:08", "published_display": "08 Jul 2026 00:11", "sentiment": "positive", "sentiment_pct": 81, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "bioAffinity Technologies Q2 CyPath\u00ae Lung Sales More Than Double Year\u2011Over\u2011Year", "summary": "bioAffinity Technologies reported a significant increase in CyPath\u00ae Lung commercial sales, more than doubling year-over-year in Q2 2026 and growing over 30% sequentially. This surge was driven by higher utilization among existing clients and a 155% rise in ordering physician offi", "url": "https://www.tradingview.com/news/tradingview:74d3690e21b33:0-bioaffinity-technologies-q2-cypath-lung-sales-more-than-double-year-over-year/", "source_name": "TradingView", "published_at": "2026-07-07T13:11:34", "published_display": "07 Jul 2026 13:11", "sentiment": "positive", "sentiment_pct": 81, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "bioAffinity reports 200% jump in lung test sales year-over-year", "summary": "bioAffinity Technologies (NASDAQ:BIAF) announced a significant increase in sales volume for its CyPath Lung diagnostic test, reporting a 200% year-over-year jump in Q2 2026 and 30% growth quarter-over-quarter. Despite a 91% stock price drop over the past year, InvestingPro analys", "url": "https://www.investing.com/news/company-news/bioaffinity-reports-200-jump-in-lung-test-sales-yearoveryear-93CH-4779337", "source_name": "Investing.com", "published_at": "2026-07-07T13:11:34", "published_display": "07 Jul 2026 13:11", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CyPath Lung sales top prior quarter as bioAffinity sees 200% growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQR0hBOEdpNk91ckZGMnRCUHlZUHo2T3lYQW8wWXNQT0Q3LUFXVG5CdFhTMXE0OE5GTE1TNHZlSURpRzdpSzc5a3V0dkZFYVpONTZjZ2tRM1Q1VHFPNVMtX0M4ZnpWMVVLZG54MkEwemJRN3RhS1VfYTNqVUxkTGtscXctLUFoemRZMnpnM1JaLVc3cXFEdk5scXc3eHRqT0Q2cE9UT2ZUQkY5VTF6eHJ0bmJscW5BanJtWmktVlNpakI?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "bioAffinity Technologies reports accelerated CyPath Lung sales, Philips partnership to boost veteran screening", "summary": "bioAffinity Technologies announced a significant increase in CyPath Lung unit sales, with April sales up nearly 300% year-over-year. The company also reported a 69% rise in ordering physician offices and clinics. Furthermore, bioAffinity is partnering with Philips and 4DMedical t", "url": "https://www.tradingview.com/news/tradingview:aede509467105:0-bioaffinity-technologies-reports-accelerated-cypath-lung-sales-philips-partnership-to-boost-veteran-screening/", "source_name": "TradingView", "published_at": "2026-06-30T21:10:08", "published_display": "30 Jun 2026 21:10", "sentiment": "positive", "sentiment_pct": 81, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CyPath Lung sales surge as bioAffinity (NASDAQ: BIAF) expands pipeline", "summary": "bioAffinity Technologies (NASDAQ: BIAF) reported a significant surge in CyPath Lung unit sales, nearly tripling in April 2026 compared to the previous year, while physician ordering sites grew by 69%. The company is expanding its pipeline with partnerships, including Philips and ", "url": "https://www.stocktitan.net/sec-filings/BIAF/8-k-bio-affinity-technologies-inc-reports-material-event-c7df91efe8ce.html", "source_name": "Stock Titan", "published_at": "2026-06-30T21:10:08", "published_display": "30 Jun 2026 21:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "bioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectively Cytotoxic to Squamous Skin Cancer Cells Without Harming Healthy Cells", "summary": "bioAffinity Technologies announced positive preclinical findings for its proprietary gene silencing technology, which selectively kills squamous and basal skin cancer cells without affecting healthy cells. This research suggests a potential topical treatment for common skin cance", "url": "https://finance.yahoo.com/healthcare/articles/bioaffinity-technologies-reports-positive-preclinical-120000747.html", "source_name": "Market source", "published_at": "2026-06-25T12:39:50", "published_display": "25 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 81, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "bioAffinity Technologies reports skin cancer siRNA preclinical results", "summary": "bioAffinity Technologies announced promising preclinical results for its novel siRNA treatment, showing it selectively destroys squamous and basal skin cancer cells in vitro while leaving healthy cells unharmed. The company plans to use these findings to develop noninvasive, targ", "url": "https://grafa.com/en/news/united-states/bioaffinity-technologies-preclinical-skin-cancer-sirna-results", "source_name": "grafa.com", "published_at": "2026-06-22T16:33:24", "published_display": "22 Jun 2026 16:33", "sentiment": "positive", "sentiment_pct": 69, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Skin cancer cells die in bioAffinity lab test, healthy cells spared", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOY3pOcTJOUTB1bFN6UU1XVFI0bHlvbWROUW1adHZOeUZfTHFWbWUyOHBqNWE3d2lRcXgtY2M3SHRSbEpEOE50MmxjbjRzRzNvRFQ5WXpoT08xZWM3MGJ6T3NheERZdHFUNWNicDZOdGNFSmpVcmsybkVoM0JIeUlSVVU5bXJobGwyZkpETWtWUmx2NUE1TXE3b09QNHRPaXN2WWhoQUh2SkJRcFozbl9Pa1JoaW5rZGh4RkE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BIOAFFINITY TECHNOLOGIES ANNOUNCES CLOSING OF $3.2 MILLION OFFERING", "summary": "BioAffinity Technologies announced the closing of a public offering of common stock and warrants, resulting in gross proceeds of approximately $3.2 million. The company issued over 1.7 million shares and an equivalent number of common stock purchase warrants, with net proceeds ex", "url": "https://www.moomoo.com/news/flash/22669540/bioaffinity-technologies-announces-closing-of-3-2-million-offering", "source_name": "Moomoo", "published_at": "2026-06-19T06:09:38", "published_display": "19 Jun 2026 06:09", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "bioAffinity Technologies (NASDAQ: BIAF) raises $3.2M in stock and pre-funded warrant sale", "summary": "bioAffinity Technologies (NASDAQ: BIAF) has successfully raised approximately $3.2 million through a \"best efforts\" public offering of common stock and pre-funded warrants. The offering included 4,000,000 securities priced at $0.80 per share or $0.793 per pre-funded warrant, with", "url": "https://www.stocktitan.net/sec-filings/BIAF/8-k-bio-affinity-technologies-inc-reports-material-event-5855e379b3d7.html", "source_name": "Stock Titan", "published_at": "2026-06-19T03:46:31", "published_display": "19 Jun 2026 03:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "bioAffinity Technologies Raises $3.2M in Best-Efforts Offering, Signs Purchase and Placement Pacts", "summary": "bioAffinity Technologies (BIAF) successfully completed a best-efforts public offering, raising approximately $3.2 million through the sale of common shares and pre-funded warrants. The company entered into a Securities Purchase Agreement with investors and a Placement Agency Agre", "url": "https://www.tradingview.com/news/tradingview:b03131bd70bfb:0-bioaffinity-technologies-raises-3-2m-in-best-efforts-offering-signs-purchase-and-placement-pacts/", "source_name": "TradingView", "published_at": "2026-06-18T20:46:31", "published_display": "18 Jun 2026 20:46", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "bioAffinity Technologies closes $3.2M public offering", "summary": "bioAffinity Technologies (NASDAQ:BIAF) has successfully closed a public offering, raising $3.2 million in gross proceeds through the sale of 4 million common shares or pre-funded warrants at around $0.80 each. The biotechnology company, specializing in noninvasive lung cancer det", "url": "https://www.investing.com/news/company-news/bioaffinity-technologies-closes-32m-public-offering-93CH-4750449", "source_name": "Investing.com", "published_at": "2026-06-18T18:46:31", "published_display": "18 Jun 2026 18:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "bioAffinity sells 4M shares, raises $3.2M in public offering", "summary": "bioAffinity Technologies (Nasdaq: BIAF) closed a previously announced public offering, raising $3.2 million in gross proceeds. The offering included 4,000,000 common shares or pre-funded warrants priced at $0.80 per share, with WallachBeth Capital acting as the sole placement age", "url": "https://www.stocktitan.net/news/BIAF/wallach-beth-capital-announces-closing-of-bio-affinity-technologies-q6opkwbjg0zd.html", "source_name": "Stock Titan", "published_at": "2026-06-18T18:46:31", "published_display": "18 Jun 2026 18:46", "sentiment": "negative", "sentiment_pct": 33, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAffinity Technologies Closes $3.2 Million Public Offering", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/bioaffinity-technologies-closes-3-2-172514792.html", "source_name": "MT Newswires", "published_at": "2026-06-18T17:25:14+00:00", "published_display": "18 Jun 2026 17:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "WallachBeth Capital Announces Closing of bioAffinity Technologies $3.2 Million Offering", "summary": "WallachBeth Capital LLC announced the closing of bioAffinity Technologies, Inc.'s public offering, raising $3.2 million in gross proceeds. The offering included 4,000,000 shares of common stock or pre-funded warrants at $0.80 per share, with WallachBeth Capital acting as the sole", "url": "https://www.prnewswire.com/news-releases/wallachbeth-capital-announces-closing-of-bioaffinity-technologies-3-2-million-offering-302804798.html", "source_name": "PR Newswire", "published_at": "2026-06-18T14:54:00", "published_display": "18 Jun 2026 14:54", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "bioAffinity (NASDAQ: BIAF) to sell 1.04M shares, up to 2.96M pre-funded warrants", "summary": "bioAffinity Technologies (NASDAQ: BIAF) has filed a prospectus to sell 1,040,000 shares of common stock at $0.80 per share and register up to 2,960,000 pre-funded warrants. The offering aims to raise estimated net proceeds of approximately $2.6 million, with a 7.5% Placement Agen", "url": "https://www.stocktitan.net/sec-filings/BIAF/424b4-bio-affinity-technologies-inc-prospectus-filed-pursuant-to-rule-bbcae265cdc6.html", "source_name": "Stock Titan", "published_at": "2026-06-18T13:39:38", "published_display": "18 Jun 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "bioAffinity raises $3.2M in stock sale priced at $0.80", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxOYzRUbTNBRllQcDlCQnFKNy1sbzlmWmM2R3pQNkVBNDNGODIwZWxDVWluTUV3c2RaVm55eU00YnRDd05uSUxYVlNaUFNqM3FvUm9OLW4zcGxyQ21NQ2NfblhiR2dOaVAyY05hbGdhQ2Q2NkRwZllUQUhnd2NhUFQxQWZTazFDX3JJMnhDUjlQaFFUY2lLQWRqajJPSTVtcTZFdVdaeERrNzM3cThYNUNSc3hyZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAffinity Technologies Prices $3.2 Million Offering; Shares Drop 13%", "summary": "BioAffinity Technologies announced the pricing of a $3.2 million underwritten public offering of 3,200,000 shares of its common stock at $1.00 per share. The offering is expected to close around June 20, 2024, and the company's shares experienced a 13% drop following the announce", "url": "https://www.moomoo.com/news/post/71670782/bioaffinity-technologies-prices-3-2-million-offering-shares-drop-13", "source_name": "Moomoo", "published_at": "2026-06-17T20:38:54", "published_display": "17 Jun 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "bioAffinity Technologies prices $3.2M public offering", "summary": "bioAffinity Technologies, Inc. has priced a public offering to raise $3.2 million. The offering includes 4,000,000 shares of common stock at $0.80 per share, with pre-funded warrants available at $0.793. WallachBeth Capital, LLC is serving as the sole placement agent, and the clo", "url": "https://scanx.trade/stock-market-news/ipo/bioaffinity-technologies-prices-3-2-million-public-offering/43250897", "source_name": "scanx.trade", "published_at": "2026-06-17T14:52:31", "published_display": "17 Jun 2026 14:52", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.2 Million Offering", "summary": "WallachBeth Capital LLC announced the pricing of a public offering for bioAffinity Technologies, Inc., a biotechnology company focused on noninvasive lung cancer detection. The offering raised $3.2 million gross proceeds through the sale of 4,000,000 shares of common stock or pre", "url": "https://www.prnewswire.com/news-releases/wallachbeth-capital-announces-pricing-of-bioaffinity-technologies-3-2-million-offering-302803249.html", "source_name": "PR Newswire", "published_at": "2026-06-17T14:40:31", "published_display": "17 Jun 2026 14:40", "sentiment": "positive", "sentiment_pct": 59, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "bioAffinity sells 4M shares, aiming to raise $3.2M", "summary": "bioAffinity Technologies is conducting a public offering of 4 million shares of common stock (or pre-funded warrants) at $0.80 per share, aiming to raise $3.2 million in gross proceeds. The offering, for which WallachBeth Capital is the sole placement agent, is expected to close ", "url": "https://www.stocktitan.net/news/BIAF/wallach-beth-capital-announces-pricing-of-bio-affinity-technologies-1nv66zbpw48y.html", "source_name": "Stock Titan", "published_at": "2026-06-17T14:40:31", "published_display": "17 Jun 2026 14:40", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "bioAffinity Technologies Inc (BIAFW) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "The article provides dividend and stock split information for bioAffinity Technologies Inc (BIAFW). It indicates that the company has distributed $0.00 in dividends over the past five years and shows no record of historical stock splits. The content is presented in a data-table f", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-biafw/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T13:11:31", "published_display": "17 Jun 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "bioAffinity Technologies, Inc. SEC Filing (Jun 17, 2026)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPMzZfVEhjdXYxWUFJM3NnaUV0WlAwZnctdmlHUzBUdzRhS0oxTlFaaC1mYng5OFh0Z28tY0hqSVJUUXhjVUFjczhxRmd5WDJOVzM3bTRGdV85NHdOX1lvUGRxa24wYW4xVnFuRm4wNlV5cVVQQ3AwYW9BakY3T015S1ltcE1kanpkNWlJRWhGTFU1cmZBbDlNTl9jVXRxUFZhMGxEbWN0Qk01ekczRVE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veteran lung health webinar from bioAffinity (BIAF) spotlights CyPath\u00ae Lung", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOZFF3UklyUmhXUHZ1VnE3ckk0enlmcFVVbkJKY09ZZ2ktdGFxbFUtUnN1MTAwTUlHR29JcFpNdVVRMVpjWi1HQzkwSmpscEpPZ1g4MGJlMms0ZUgzb25MS0FLSm05dWRMUXlKX0VXTDdLaVJGRGVuY0hzZnNJMkljSDBWRUFsNENpNjFtZGRHX2pSNnE1UnY0cldsOE5xTl9xTFZoeExvaHhic2lYaDl4b1RyU25lUWFjc2c?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "bioAffinity Stock Surges 113.8% in 3 Months: What's Driving the Rally?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPX1I3dXZOZEJDelRVTG0xV0pUdG5tRkpYemNKcVhFd1p6RWJCZmcyRTFBOTB5WHluR09Tbk5mTExlQnNpaEVkUHJuOFNaV3AzeEdYaGlibTh0RXViSVVwZU8tVlQ2VXB6QWxYZXl6am8zMGV1Z2ZUNHQ5WHA0WlN6OWxqRVJLWEJtbFZYUjdZaDY3dWZ1YUtxb1Jicw?oc=5", "source_name": "Market source", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Doctors will share real patient cases in bioAffinity lung test webinar", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQTExJS3hINzJFRURqYTBjSnRPMGFsX183Y09LWHFhbG9zN3l1TFNzVEp1dUVoUktUajhDV3Vnd0pnZHYxdnAyZy15SWs0ZEZEU29QZnhMMTM4SlNNM2FTaE45NUVpSzlKN1dHUFVWenFsSnI3NjFsZUFtQjBBQUhLRGNMOHV0OVJ1Ym1QRm9SRU42NmlSZ3NKMzhBU3ZPbU1BOThUZDB4N1RpeGVPV1ZaNC1fRE1XVEIzd3hzVUVaaw?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "bioAffinity Technologies shares soar as investors react to upbeat CyPath Lung growth update and 2026 outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxOSXUzOXhqbEFhOFFJSE9xbjY2eDc4SXZ4RlJPaS15UEZkUUxvMUVXREdweldKZExtMXNjVEUzNWlWUTZMcUJXd2FManFkTGZ1cnZpUkR2ajVGbGEta3F1R0JvMGVPMXduZXlkWHFsLVpEdUpCSXU2ZzVUQUtfbVdndnNLZWJGZWd5ckh0V1UzTE9lWXN0ZzdkekRKcENfSDZQOUsxQ3ZYNkVXUkNxQXktY1BLaFIyemlrVVB2WktuLURVeWJuYUxITjlaMUpoYnRKTHcxcEpDeWQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "bioAffinity Tech (BIAF) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBuOHNESDRoUTBXSmRReFY0aUwxZ1FRa1REcXJkMmVqbFRYN1d6Q216M3NMRFluQ200eHRSTk81ZWdkajZPLWVEaEFSMFlHRmxGLUZr?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T20:37:30+00:00", "published_display": "24 Apr 2025 20:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "bioAffinity Technologies (BIAF) Stock Price, News & Analysis $BIAF", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE9DR2lOSWlnX21YSWg4M3dlZ205MGJGdjdwc1N6TVJabW5kOEVTQXBwRkhVcDRJRnZfbFZ6NU90cVF1SWtwaWZidjhGVkVSMkQtTnFZQUpnRlpVQQ?oc=5", "source_name": "MarketBeat", "published_at": "2022-08-24T05:38:17+00:00", "published_display": "24 Aug 2022 05:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Transcript : BioAffinity Technologies, Inc. - Special Call", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOTkM5dXZ2aEZsejJkNFZfZ05pUU5MMTNRa2FDeFJpVW1JT3ExcEZhclZ3WVJvQmYySUttTmNHUkM1S1g1cm1uRmtLamZmb2d4V2VyVk1PbEN3YVl5QWt5UWU3bko0Vmgza3lpZlFlU0ZlSi0ya3JTalEyREhCc0x1ZVpjeVN3eDhJbkpjdmZxOVMtLS05MC1iZzlWMnJnWmtEMjZiU2NuQ2E?oc=5", "source_name": "marketscreener.com", "published_at": "2026-07-22T01:20:35+00:00", "published_display": "22 Jul 2026 01:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certain Common Stock of bioAffinity Technologies, Inc. are subject to a Lock-Up Agreement Ending on 19-JUL-2026.", "summary": "Certain Common Stock of bioAffinity Technologies, Inc. are subject to a lock-up agreement that concludes on July 19, 2026. This agreement restricts officers and directors from selling or otherwise disposing of their common stock for 31 days, from June 18, 2026, to July 19, 2026, ", "url": "https://www.marketscreener.com/news/certain-common-stock-of-bioaffinity-technologies-inc-are-subject-to-a-lock-up-agreement-ending-on-ce7f51dadf81f427", "source_name": "www.marketscreener.com", "published_at": "2026-07-19T03:41:33", "published_display": "19 Jul 2026 03:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "bioAffinity Technologies Initiates New Study for Expanding CyPath Lung Tech", "summary": "bioAffinity Technologies is launching a pilot study with Brooke Army Medical Center to develop diagnostic tests for asthma and COPD. This research aims to identify inflammatory biomarkers using their proprietary flow cytometry+AI technology to personalize treatment approaches. Th", "url": "https://www.mpo-mag.com/breaking-news/bioaffinity-technologies-initiates-new-study-for-expanding-cypath-lung-tech/", "source_name": "Medical Product Outsourcing", "published_at": "2026-07-15T14:12:13", "published_display": "15 Jul 2026 14:12", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "bioAffinity Technologies Inc Warrant 2022- on bioAffinity Financial Disclosures & SEC Filings", "summary": "This page provides access to SEC filings and other financial documents for bioAffinity Technologies, Inc. (BIAFW). It lists various reports including 10-K, 10-Q, and 8-K filings from 2022 to the projected Q1 FY2026, detailing earnings releases, corporate events, and operational u", "url": "https://www.tradingview.com/symbols/NASDAQ-BIAFW/documents/?exchange=NASDAQ", "source_name": "TradingView", "published_at": "2026-07-11T13:09:56", "published_display": "11 Jul 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BIAF Stock Plunges 77% in 3 Months: Should You Still Hold or Sell?", "summary": "Shares of bioAffinity Technologies, Inc. (BIAF) have plummeted 77% in the past three months, significantly underperforming its industry and market benchmarks despite strong year-over-year growth in commercial sales for its CyPath Lung product and promising preclinical findings. T", "url": "https://uk.finance.yahoo.com/news/biaf-stock-plunges-77-3-173400281.html", "source_name": "Market source", "published_at": "2026-07-09T17:44:04", "published_display": "09 Jul 2026 17:44", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "bioAffinity Technologies\u2019 Quarterly CyPath\u00ae Lung Sales Double to New Record as Commercial Momentum Continues", "summary": "bioAffinity Technologies announced a significant increase in commercial sales for its CyPath\u00ae Lung diagnostic test, with sales for Q2 2026 doubling year-over-year and growing over 30% from the previous quarter. This growth is attributed to increased utilization by existing client", "url": "https://www.businesswire.com/news/home/20260707410622/en/bioAffinity-Technologies-Quarterly-CyPath-Lung-Sales-Double-to-New-Record-as-Commercial-Momentum-Continues", "source_name": "Business Wire", "published_at": "2026-07-08T00:11:08", "published_display": "08 Jul 2026 00:11", "sentiment": "positive", "sentiment_pct": 81, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "bioAffinity Technologies Q2 CyPath\u00ae Lung Sales More Than Double Year\u2011Over\u2011Year", "summary": "bioAffinity Technologies reported a significant increase in CyPath\u00ae Lung commercial sales, more than doubling year-over-year in Q2 2026 and growing over 30% sequentially. This surge was driven by higher utilization among existing clients and a 155% rise in ordering physician offi", "url": "https://www.tradingview.com/news/tradingview:74d3690e21b33:0-bioaffinity-technologies-q2-cypath-lung-sales-more-than-double-year-over-year/", "source_name": "TradingView", "published_at": "2026-07-07T13:11:34", "published_display": "07 Jul 2026 13:11", "sentiment": "positive", "sentiment_pct": 81, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "bioAffinity reports 200% jump in lung test sales year-over-year", "summary": "bioAffinity Technologies (NASDAQ:BIAF) announced a significant increase in sales volume for its CyPath Lung diagnostic test, reporting a 200% year-over-year jump in Q2 2026 and 30% growth quarter-over-quarter. Despite a 91% stock price drop over the past year, InvestingPro analys", "url": "https://www.investing.com/news/company-news/bioaffinity-reports-200-jump-in-lung-test-sales-yearoveryear-93CH-4779337", "source_name": "Investing.com", "published_at": "2026-07-07T13:11:34", "published_display": "07 Jul 2026 13:11", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CyPath Lung sales top prior quarter as bioAffinity sees 200% growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQR0hBOEdpNk91ckZGMnRCUHlZUHo2T3lYQW8wWXNQT0Q3LUFXVG5CdFhTMXE0OE5GTE1TNHZlSURpRzdpSzc5a3V0dkZFYVpONTZjZ2tRM1Q1VHFPNVMtX0M4ZnpWMVVLZG54MkEwemJRN3RhS1VfYTNqVUxkTGtscXctLUFoemRZMnpnM1JaLVc3cXFEdk5scXc3eHRqT0Q2cE9UT2ZUQkY5VTF6eHJ0bmJscW5BanJtWmktVlNpakI?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "bioAffinity Technologies reports accelerated CyPath Lung sales, Philips partnership to boost veteran screening", "summary": "bioAffinity Technologies announced a significant increase in CyPath Lung unit sales, with April sales up nearly 300% year-over-year. The company also reported a 69% rise in ordering physician offices and clinics. Furthermore, bioAffinity is partnering with Philips and 4DMedical t", "url": "https://www.tradingview.com/news/tradingview:aede509467105:0-bioaffinity-technologies-reports-accelerated-cypath-lung-sales-philips-partnership-to-boost-veteran-screening/", "source_name": "TradingView", "published_at": "2026-06-30T21:10:08", "published_display": "30 Jun 2026 21:10", "sentiment": "positive", "sentiment_pct": 81, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CyPath Lung sales surge as bioAffinity (NASDAQ: BIAF) expands pipeline", "summary": "bioAffinity Technologies (NASDAQ: BIAF) reported a significant surge in CyPath Lung unit sales, nearly tripling in April 2026 compared to the previous year, while physician ordering sites grew by 69%. The company is expanding its pipeline with partnerships, including Philips and ", "url": "https://www.stocktitan.net/sec-filings/BIAF/8-k-bio-affinity-technologies-inc-reports-material-event-c7df91efe8ce.html", "source_name": "Stock Titan", "published_at": "2026-06-30T21:10:08", "published_display": "30 Jun 2026 21:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "bioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectively Cytotoxic to Squamous Skin Cancer Cells Without Harming Healthy Cells", "summary": "bioAffinity Technologies announced positive preclinical findings for its proprietary gene silencing technology, which selectively kills squamous and basal skin cancer cells without affecting healthy cells. This research suggests a potential topical treatment for common skin cance", "url": "https://finance.yahoo.com/healthcare/articles/bioaffinity-technologies-reports-positive-preclinical-120000747.html", "source_name": "Market source", "published_at": "2026-06-25T12:39:50", "published_display": "25 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 81, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "bioAffinity Technologies reports skin cancer siRNA preclinical results", "summary": "bioAffinity Technologies announced promising preclinical results for its novel siRNA treatment, showing it selectively destroys squamous and basal skin cancer cells in vitro while leaving healthy cells unharmed. The company plans to use these findings to develop noninvasive, targ", "url": "https://grafa.com/en/news/united-states/bioaffinity-technologies-preclinical-skin-cancer-sirna-results", "source_name": "grafa.com", "published_at": "2026-06-22T16:33:24", "published_display": "22 Jun 2026 16:33", "sentiment": "positive", "sentiment_pct": 69, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Skin cancer cells die in bioAffinity lab test, healthy cells spared", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOY3pOcTJOUTB1bFN6UU1XVFI0bHlvbWROUW1adHZOeUZfTHFWbWUyOHBqNWE3d2lRcXgtY2M3SHRSbEpEOE50MmxjbjRzRzNvRFQ5WXpoT08xZWM3MGJ6T3NheERZdHFUNWNicDZOdGNFSmpVcmsybkVoM0JIeUlSVVU5bXJobGwyZkpETWtWUmx2NUE1TXE3b09QNHRPaXN2WWhoQUh2SkJRcFozbl9Pa1JoaW5rZGh4RkE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BIOAFFINITY TECHNOLOGIES ANNOUNCES CLOSING OF $3.2 MILLION OFFERING", "summary": "BioAffinity Technologies announced the closing of a public offering of common stock and warrants, resulting in gross proceeds of approximately $3.2 million. The company issued over 1.7 million shares and an equivalent number of common stock purchase warrants, with net proceeds ex", "url": "https://www.moomoo.com/news/flash/22669540/bioaffinity-technologies-announces-closing-of-3-2-million-offering", "source_name": "Moomoo", "published_at": "2026-06-19T06:09:38", "published_display": "19 Jun 2026 06:09", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "bioAffinity Technologies (NASDAQ: BIAF) raises $3.2M in stock and pre-funded warrant sale", "summary": "bioAffinity Technologies (NASDAQ: BIAF) has successfully raised approximately $3.2 million through a \"best efforts\" public offering of common stock and pre-funded warrants. The offering included 4,000,000 securities priced at $0.80 per share or $0.793 per pre-funded warrant, with", "url": "https://www.stocktitan.net/sec-filings/BIAF/8-k-bio-affinity-technologies-inc-reports-material-event-5855e379b3d7.html", "source_name": "Stock Titan", "published_at": "2026-06-19T03:46:31", "published_display": "19 Jun 2026 03:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "bioAffinity Technologies Raises $3.2M in Best-Efforts Offering, Signs Purchase and Placement Pacts", "summary": "bioAffinity Technologies (BIAF) successfully completed a best-efforts public offering, raising approximately $3.2 million through the sale of common shares and pre-funded warrants. The company entered into a Securities Purchase Agreement with investors and a Placement Agency Agre", "url": "https://www.tradingview.com/news/tradingview:b03131bd70bfb:0-bioaffinity-technologies-raises-3-2m-in-best-efforts-offering-signs-purchase-and-placement-pacts/", "source_name": "TradingView", "published_at": "2026-06-18T20:46:31", "published_display": "18 Jun 2026 20:46", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "bioAffinity Technologies closes $3.2M public offering", "summary": "bioAffinity Technologies (NASDAQ:BIAF) has successfully closed a public offering, raising $3.2 million in gross proceeds through the sale of 4 million common shares or pre-funded warrants at around $0.80 each. The biotechnology company, specializing in noninvasive lung cancer det", "url": "https://www.investing.com/news/company-news/bioaffinity-technologies-closes-32m-public-offering-93CH-4750449", "source_name": "Investing.com", "published_at": "2026-06-18T18:46:31", "published_display": "18 Jun 2026 18:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "bioAffinity sells 4M shares, raises $3.2M in public offering", "summary": "bioAffinity Technologies (Nasdaq: BIAF) closed a previously announced public offering, raising $3.2 million in gross proceeds. The offering included 4,000,000 common shares or pre-funded warrants priced at $0.80 per share, with WallachBeth Capital acting as the sole placement age", "url": "https://www.stocktitan.net/news/BIAF/wallach-beth-capital-announces-closing-of-bio-affinity-technologies-q6opkwbjg0zd.html", "source_name": "Stock Titan", "published_at": "2026-06-18T18:46:31", "published_display": "18 Jun 2026 18:46", "sentiment": "negative", "sentiment_pct": 33, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAffinity Technologies Closes $3.2 Million Public Offering", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/bioaffinity-technologies-closes-3-2-172514792.html", "source_name": "MT Newswires", "published_at": "2026-06-18T17:25:14+00:00", "published_display": "18 Jun 2026 17:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "WallachBeth Capital Announces Closing of bioAffinity Technologies $3.2 Million Offering", "summary": "WallachBeth Capital LLC announced the closing of bioAffinity Technologies, Inc.'s public offering, raising $3.2 million in gross proceeds. The offering included 4,000,000 shares of common stock or pre-funded warrants at $0.80 per share, with WallachBeth Capital acting as the sole", "url": "https://www.prnewswire.com/news-releases/wallachbeth-capital-announces-closing-of-bioaffinity-technologies-3-2-million-offering-302804798.html", "source_name": "PR Newswire", "published_at": "2026-06-18T14:54:00", "published_display": "18 Jun 2026 14:54", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "bioAffinity (NASDAQ: BIAF) to sell 1.04M shares, up to 2.96M pre-funded warrants", "summary": "bioAffinity Technologies (NASDAQ: BIAF) has filed a prospectus to sell 1,040,000 shares of common stock at $0.80 per share and register up to 2,960,000 pre-funded warrants. The offering aims to raise estimated net proceeds of approximately $2.6 million, with a 7.5% Placement Agen", "url": "https://www.stocktitan.net/sec-filings/BIAF/424b4-bio-affinity-technologies-inc-prospectus-filed-pursuant-to-rule-bbcae265cdc6.html", "source_name": "Stock Titan", "published_at": "2026-06-18T13:39:38", "published_display": "18 Jun 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "bioAffinity raises $3.2M in stock sale priced at $0.80", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxOYzRUbTNBRllQcDlCQnFKNy1sbzlmWmM2R3pQNkVBNDNGODIwZWxDVWluTUV3c2RaVm55eU00YnRDd05uSUxYVlNaUFNqM3FvUm9OLW4zcGxyQ21NQ2NfblhiR2dOaVAyY05hbGdhQ2Q2NkRwZllUQUhnd2NhUFQxQWZTazFDX3JJMnhDUjlQaFFUY2lLQWRqajJPSTVtcTZFdVdaeERrNzM3cThYNUNSc3hyZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAffinity Technologies Prices $3.2 Million Offering; Shares Drop 13%", "summary": "BioAffinity Technologies announced the pricing of a $3.2 million underwritten public offering of 3,200,000 shares of its common stock at $1.00 per share. The offering is expected to close around June 20, 2024, and the company's shares experienced a 13% drop following the announce", "url": "https://www.moomoo.com/news/post/71670782/bioaffinity-technologies-prices-3-2-million-offering-shares-drop-13", "source_name": "Moomoo", "published_at": "2026-06-17T20:38:54", "published_display": "17 Jun 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "bioAffinity Technologies prices $3.2M public offering", "summary": "bioAffinity Technologies, Inc. has priced a public offering to raise $3.2 million. The offering includes 4,000,000 shares of common stock at $0.80 per share, with pre-funded warrants available at $0.793. WallachBeth Capital, LLC is serving as the sole placement agent, and the clo", "url": "https://scanx.trade/stock-market-news/ipo/bioaffinity-technologies-prices-3-2-million-public-offering/43250897", "source_name": "scanx.trade", "published_at": "2026-06-17T14:52:31", "published_display": "17 Jun 2026 14:52", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.2 Million Offering", "summary": "WallachBeth Capital LLC announced the pricing of a public offering for bioAffinity Technologies, Inc., a biotechnology company focused on noninvasive lung cancer detection. The offering raised $3.2 million gross proceeds through the sale of 4,000,000 shares of common stock or pre", "url": "https://www.prnewswire.com/news-releases/wallachbeth-capital-announces-pricing-of-bioaffinity-technologies-3-2-million-offering-302803249.html", "source_name": "PR Newswire", "published_at": "2026-06-17T14:40:31", "published_display": "17 Jun 2026 14:40", "sentiment": "positive", "sentiment_pct": 59, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "bioAffinity sells 4M shares, aiming to raise $3.2M", "summary": "bioAffinity Technologies is conducting a public offering of 4 million shares of common stock (or pre-funded warrants) at $0.80 per share, aiming to raise $3.2 million in gross proceeds. The offering, for which WallachBeth Capital is the sole placement agent, is expected to close ", "url": "https://www.stocktitan.net/news/BIAF/wallach-beth-capital-announces-pricing-of-bio-affinity-technologies-1nv66zbpw48y.html", "source_name": "Stock Titan", "published_at": "2026-06-17T14:40:31", "published_display": "17 Jun 2026 14:40", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "bioAffinity Technologies Inc (BIAFW) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "The article provides dividend and stock split information for bioAffinity Technologies Inc (BIAFW). It indicates that the company has distributed $0.00 in dividends over the past five years and shows no record of historical stock splits. The content is presented in a data-table f", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-biafw/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T13:11:31", "published_display": "17 Jun 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "bioAffinity Technologies, Inc. SEC Filing (Jun 17, 2026)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPMzZfVEhjdXYxWUFJM3NnaUV0WlAwZnctdmlHUzBUdzRhS0oxTlFaaC1mYng5OFh0Z28tY0hqSVJUUXhjVUFjczhxRmd5WDJOVzM3bTRGdV85NHdOX1lvUGRxa24wYW4xVnFuRm4wNlV5cVVQQ3AwYW9BakY3T015S1ltcE1kanpkNWlJRWhGTFU1cmZBbDlNTl9jVXRxUFZhMGxEbWN0Qk01ekczRVE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veteran lung health webinar from bioAffinity (BIAF) spotlights CyPath\u00ae Lung", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOZFF3UklyUmhXUHZ1VnE3ckk0enlmcFVVbkJKY09ZZ2ktdGFxbFUtUnN1MTAwTUlHR29JcFpNdVVRMVpjWi1HQzkwSmpscEpPZ1g4MGJlMms0ZUgzb25MS0FLSm05dWRMUXlKX0VXTDdLaVJGRGVuY0hzZnNJMkljSDBWRUFsNENpNjFtZGRHX2pSNnE1UnY0cldsOE5xTl9xTFZoeExvaHhic2lYaDl4b1RyU25lUWFjc2c?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "bioAffinity Stock Surges 113.8% in 3 Months: What's Driving the Rally?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPX1I3dXZOZEJDelRVTG0xV0pUdG5tRkpYemNKcVhFd1p6RWJCZmcyRTFBOTB5WHluR09Tbk5mTExlQnNpaEVkUHJuOFNaV3AzeEdYaGlibTh0RXViSVVwZU8tVlQ2VXB6QWxYZXl6am8zMGV1Z2ZUNHQ5WHA0WlN6OWxqRVJLWEJtbFZYUjdZaDY3dWZ1YUtxb1Jicw?oc=5", "source_name": "Market source", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Doctors will share real patient cases in bioAffinity lung test webinar", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQTExJS3hINzJFRURqYTBjSnRPMGFsX183Y09LWHFhbG9zN3l1TFNzVEp1dUVoUktUajhDV3Vnd0pnZHYxdnAyZy15SWs0ZEZEU29QZnhMMTM4SlNNM2FTaE45NUVpSzlKN1dHUFVWenFsSnI3NjFsZUFtQjBBQUhLRGNMOHV0OVJ1Ym1QRm9SRU42NmlSZ3NKMzhBU3ZPbU1BOThUZDB4N1RpeGVPV1ZaNC1fRE1XVEIzd3hzVUVaaw?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "bioAffinity Technologies shares soar as investors react to upbeat CyPath Lung growth update and 2026 outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxOSXUzOXhqbEFhOFFJSE9xbjY2eDc4SXZ4RlJPaS15UEZkUUxvMUVXREdweldKZExtMXNjVEUzNWlWUTZMcUJXd2FManFkTGZ1cnZpUkR2ajVGbGEta3F1R0JvMGVPMXduZXlkWHFsLVpEdUpCSXU2ZzVUQUtfbVdndnNLZWJGZWd5ckh0V1UzTE9lWXN0ZzdkekRKcENfSDZQOUsxQ3ZYNkVXUkNxQXktY1BLaFIyemlrVVB2WktuLURVeWJuYUxITjlaMUpoYnRKTHcxcEpDeWQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "bioAffinity Tech (BIAF) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBuOHNESDRoUTBXSmRReFY0aUwxZ1FRa1REcXJkMmVqbFRYN1d6Q216M3NMRFluQ200eHRSTk81ZWdkajZPLWVEaEFSMFlHRmxGLUZr?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T20:37:30+00:00", "published_display": "24 Apr 2025 20:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "bioAffinity Technologies (BIAF) Stock Price, News & Analysis $BIAF", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE9DR2lOSWlnX21YSWg4M3dlZ205MGJGdjdwc1N6TVJabW5kOEVTQXBwRkhVcDRJRnZfbFZ6NU90cVF1SWtwaWZidjhGVkVSMkQtTnFZQUpnRlpVQQ?oc=5", "source_name": "MarketBeat", "published_at": "2022-08-24T05:38:17+00:00", "published_display": "24 Aug 2022 05:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 83, "total_relevant": 35, "sentiment_summary": {"positive": 17, "negative": 3, "neutral": 15, "score": 58, "total": 35, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 88, "events": [{"event": "general", "label": "Market update", "weight": 15.4, "count": 28}, {"event": "earnings", "label": "Earnings", "weight": 2.2, "count": 4}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 17, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 0.7, "latest_week": "2026-07-17", "one_week_move": -8.2, "four_week_move": -15.9, "twelve_week_move": -68.4, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.76708, "market_dynamics_buy_signal": false, "relative_strength": -78.98037, "fair_value_gap": -97.5, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 41.5267, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-8.2% over one week, -15.9% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 70, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 12}, {"label": "TradingView", "count": 4}, {"label": "Market source", "count": 3}, {"label": "Investing.com", "count": 2}, {"label": "Moomoo", "count": 2}, {"label": "PR Newswire", "count": 2}, {"label": "marketscreener.com", "count": 1}, {"label": "www.marketscreener.com", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 35}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 28}, {"label": "Earnings", "count": 4}, {"label": "Deals and strategy", "count": 1}, {"label": "Capital return", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "58/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "88/100 classification confidence."}, {"label": "Company focus", "value": "35", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-8.2% over one week, -15.9% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Transcript : BioAffinity Technologies, Inc. - Special Call"}], "updated_at": "2026-07-22T06:02:30.239179+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}